Molecule associated with onset of gout, and method and kit for evaluating diathesis of uric acid-related diseases and inflammation-related diseases, and inspection object and drug

Abstract

To specify a molecule associated with the onset of gout so as to provide a method for evaluating a diathesis of uric acid-related diseases and a diathesis of inflammation-related diseases, an evaluation kit for carrying out the method, an inspection object, and a drug, on the basis of the molecule specified above, for contributing to the early treatment and prevention of the uric acid-related diseases and inflammation-related diseases. The molecule includes any one protein and cDNA of CNIH2-PACS1, ALDH2, MYL2-CUX2, GCKR, MAP3K11, NPT4, ABCG2, HIST1H2BF / HIST1H4E, HIST1H2BE / HIST1H4D and FAM35A, or proteins of combination thereof with GLUT9, NPT1, URAT1, or NXRN2, and is capable of selectively inducing gout. A molecule includes protein and cDNA of an ABCG2 variant and is capable of selectively and ATP-dependently decreasing urate excretion.

Description

TECHNICAL FIELD[0001]The present invention relates to a molecule associated with the onset of gout, as well as a method for evaluating a uric acid-related disease diathesis and an inflammation-related disease diathesis, and an evaluation kit for carrying out the method, and also an inspection object and a drug relating to the method and kit.BACKGROUND ART[0002]Recently, gout patients have increased and the onset age has become younger. Gout is a disease caused by deposition of monosodium urate crystals in tissue, and often has the onset as a result of inflammation of the joint. Furthermore, gout is frequently found in hyperuricemia patients, and has long been known to have heritable components.[0003]Gout is often complicated with hypertension, obesity, diabetes, coronary artery diseases, cerebrovascular diseases, kidney diseases, and the like. Furthermore, inflammation-related diseases include rheumatoid arthritis, infertility, and the like. Thus, early treatment and prevention of t...

AI Technical Summary

Benefits of technology

The present invention helps to identify and treat diseases related to uric acid regulation, particularly gout. By measuring the function of genes associated with gout, the invention can help predict who should start treatment and which medications will work best. This will reduce medical costs and physical burdens on patients, and also help with early prevention and treatment of individual cases. The invention also provides information on the effectiveness of various types of medication and lifestyle measures, such as diet targets.

Problems solved by technology

Gout is often complicated with hypertension, obesity, diabetes, coronary artery diseases, cerebrovascular diseases, kidney diseases, and the like.

However, the prior arts disclose the ABCG2 as a transporter of a drug, but not disclose its involvement in urate transport.

However, it has not been clarified what types of hyperuricemia patients develop gout, and what types of hyperuricemia patients do not develop gout.

On the other hand, some cases develop gout although the serum uric acid level is not so high, and physical and economic burden of the gout patients have been large.

Furthermore, when variations are found, it is desirable that specific measures, for example, a target values for diet be set, but they have not been able to be made by conventional technology.

Images